By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology is now available. According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "Carboxypeptidase N(CPN) is important in regulating vasoactive peptide hormones, growth factors, and cytokines by specifically cleaving their C-terminal basic residues. We investigated whether circulating peptides specifically cleaved by CPN in the tumor microenvironment can be stage-specific indicators of breast cancer."
Our news editors obtained a quote from the research from Cornell University, "CPN activity was measured using an ex vivo peptide cleavage assay by incubating synthesized C3f peptide (His(6)-C3f_S-1304-R-1320-His(6)) in interstitial fluids of breast tumors and adjacent normal breast tissues in mice with orthotopic implantation of the human cell line MDA-MB-231. The nature and extent of peptide cleavage by CPN was investigated by fragment profiling using nanopore fractionation and mass spectrometry. The fragment profiles in interstitial fluid correlated with concentrations of CPN-catalyzed peptides in blood samples taken from the tumor-bearing mice, healthy women, and breast cancer patients. CPN expression in the same set of samples was further examined by immunohistochemistry and immunoblotting. We showed that generation of C3f_ R-1310-L-1319 specifically correlated with the CPN expression level. In both the mouse and clinical patient samples, CPN was clearly increased in tumor tissues compared with normal breast tissue, whereas corresponding CPN abundance in blood remained constant. Concentrations of 6 CPN-catalyzed peptides predominantly increased in sera taken from the mice (n = 8) at 2 weeks after orthotopic implantation. Six homologous peptides displayed significantly higher expression in the patients' plasma as early as the first pathologic stage of breast cancer. Circulating CPN-catalyzed peptide concentrations reflect the CPN activity in tumors."
According to the news editors, the research concluded: "These biomarkers show strong potential for the noninvasive and early diagnosis of breast cancer."
For more information on this research see: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer. Clinical Chemistry, 2014;60(1):233-242. Clinical Chemistry can be contacted at: Amer Assoc Clinical Chemistry, 2101 L Street NW, Suite 202, Washington, DC 20037-1526, USA (see also Oncology).
The news editors report that additional information may be obtained by contacting Y.J. Li, Cornell University, Weill Cornell Med College, Dept. of Internal Med, New York, NY 10021, United States. Additional authors for this research include Y.G. Li, T. Chen, A.S. Kuklina, P. Bernard, F.J. Esteva, H.F. Shen, M. Ferrari and Y. Hu.
Keywords for this news article include: Oncology, Peptides, Proteins, Proteomics, Amino Acids, New York City, United States, Breast Cancer, Women's Health, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC